Pharmacist and Diploma-Pharmacist Iris Minichmayr

Iris Minichmayr

Institute of Pharmacy

Clinical Pharmacy & Biochemistry

Freie Universität Berlin

Address Kelchstr. 31
Room 130A
12169 Berlin
Telephone 030-838 50662
Email iris.minichmayr[at]fu-berlin.de

Curriculum Vitae


since 04/2012

PhD student (Graduate Research Training Program „PharMetrX“, Pharmacometrics & Computational Disease Modeling) in the Clinical pharmacy research group headed by Prof. Dr. Charlotte Kloft

02/2010-03/2012

Pharmacist, St. Martin Gesundheitsapotheke, Apotheke an der Kaiserstraße, Apotheke am Naschmarkt, Vienna

01/2010 Austrian Pharmacy Board Exam; Registration as pharmacist
02/2009-01/2010 Pre-registration pharmacist, Apotheke am Naschmarkt, Vienna
03/2007-06/2007 Internship, Hospital pharmacy of Clínica Dávila, Santiago de Chile
02/2007-09/2007 Universidad de Chile, Santiago de Chile: Joint Study Exchange Fellowship  
07/2004, 07-08/2005,
07-08/2006

Intern, Department of Quality Assurance, Nycomed Austria GmbH, Linz, Austria

10/2002-01/2009

University of Vienna, Field of study: Pharmacy

Research thesis at the Department of Clinical Pharmacy, Prof. Walter Jäger

Original title: Expression of Organic Anion Transporting Polypeptides OATP1B3 and OATP3A1 in Ovarian Cancer Cell Lines: Impact on Paclitaxel Resistance and Cell Growth

6/2002 Matura (A-levels), Bundesgymnasium WerndlPark Steyr, Austria



 


 

 

 


 

Focus of research

 
[Forschungslinie 2]: Pharmacometric data analysis


Sufficiently high drug concentrations at the target site of action form a key prerequisite for
drug effectiveness and treatment success. However, these may substantially differ from corres- ponding plasma concentrations. Microdialysis has emerged as the method of choice for the determination of unbound, i.e. pharmacologically active, interstitial fluid concentrations of various drugs in peripheral tissues.

My PhD project addresses the analysis of plasma and microdialysis data by means of popu- lation pharmacokinetic modelling. Based on clinical data originating from heterogeneous studies involving both healthy volunteers and divergent patient groups, mathematical models shall be built enabling the description and prediction of concentration-time profiles in plasma and at drug target sites. Furthermore, different sources of variability are elucidated and conse- quently aimed to be assigned to explanatory patient-, disease-, measurement- or study-related factors (covariates). 

Ideally, the developed models will help to assess whether currently employed therapy regi-
mens provide adequate, thus effective and safe concentrations in different compartments of
the body and hence aid dosage adjustments in distinct patient populations (e.g. critically ill patients). For instance, antibiotic regimens will be evaluated and new dosing recommendations established in order to prevent both toxicity and therapeutic failure or emergence of bacterial resistance.